Dupixent Drives Sanofi Growth Again Amid Pipeline Renewal
First Quarter Earnings Show Increased R&D Spend
The major’s atopic dermatitis blockbuster made more than €1.6bn this quarter, but the firm’s R&D costs are rising as it attempts to add some fresh blood to its stagnating pipeline.
You may also be interested in...
Big pharma players have embraced a tricky operating environment in 2022 so far, treading a tightrope with political and financial challenges impacting their decision making and threatening to blow them off balance. However, what is not in doubt is the healthy growth experienced by those companies based around mainland Europe and the UK.
The US biotech has nabbed a couple of Sanofi’s Phase III CNS candidates, its third deal of the year aimed at transforming the neuropsychiatry market.
Looking to catch up with leaders in in the field of next-generation antibodies, Sanofi has struck a deal with IGM Biosciences for three cancer and three auto-immune/inflammation IgM candidates that hold the promise of greater efficacy.